Page last updated: 2024-11-02

pirenzepine and Anti-MuSK Myasthenia Gravis

pirenzepine has been researched along with Anti-MuSK Myasthenia Gravis in 1 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Research Excerpts

ExcerptRelevanceReference
" Pyridostigmine had a higher elimination (2 h-1) than the absorption rate constant (0."1.29Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. ( Breyer-Pfaff, U; Eiermann, B; Maier, U; Schumm, F; Sommer, N; Winne, D, 1993)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Eiermann, B1
Sommer, N1
Winne, D1
Schumm, F1
Maier, U1
Breyer-Pfaff, U1

Other Studies

1 other study available for pirenzepine and Anti-MuSK Myasthenia Gravis

ArticleYear
Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine.
    Xenobiotica; the fate of foreign compounds in biological systems, 1993, Volume: 23, Issue:11

    Topics: Adolescent; Adult; Aged; Drug Interactions; Female; Glomerular Filtration Rate; Humans; Kidney Glome

1993